Document is current
Any future updates will be listed below
-
Authors
Longato, Enrico
Di Camillo, Barbara
Sparacino, Giovanni
Tramontan, Lara
Avogaro, Angelo
Fadini, Gian Paolo http://orcid.org/0000-0002-6510-2097
-
Funding
Funding for this research was provided by:
Università degli Studi di Padova
Ministero dell’Istruzione, dell’Università e della Ricerca (Departments of Excellence)
Italian Diabetes Society
- License Information
-
More Information
Article History
Received: 13 September 2021
Accepted: 4 November 2021
First Online: 13 November 2021
Declarations
:
: The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki. All the data used in this study were previously anonymized as per the Italian law concerning their usage for research and governance purposes. Study conduct was approved by the data owner board (Arsenàl.IT) and a formal ethics approval was deemed not necessary. Based on national regulations for retrospective studies on anonymized administrative claims, patients’ informed consent was not collected.
: Not applicable.
: AA received research grants, lecture or advisory board fees from Merck Sharp & Dome, AstraZeneca, Novartis, Boeringher-Ingelheim, Sanofi, Mediolanum, Janssen, Novo Nordisk, Lilly, Servier, and Takeda. GPF received lecture fees or grant support from Abbott, AstraZeneca, Boehringer, Lilly, Merck-Sharp-Dome, Mundipharma, Novartis, Novo Nordisk, Sanofi, Servier. EL, BDC, GS, LT have nothing to disclose.
